Our professionals

Dr. Sandra Hervás Stubbs

Principal investigator of the Adoptive Cell Therapy research group. .
Current research focused on improving the efficacy of T-cell therapy for the treatment of solid tumors, including CAR-T cells, but with special attention to the development of TCR therapies.

Be part of: Cima Universidad de Navarra

INDEX H 39

Bachelor in Biological Sciences, Universidad de Navarra (Spain), 1990
PhD in Sciences, Universidad de Navarra (Spain), 1995
Research Assistant, Public University of Navarra (1996-2002)
Postoctoral, Dr. Claude Leclerc’s laboratoru, Pasteur Institute in Paris (France) (2003-2006)
Ramon y Cajal, Center for Applied Medical Researc, Universidad de Navarra (Spain), (2007-2012)
Principal Investigator, Center for Applied Medical Researc, Universidad de Navarra (Spain), (2013-)

Development of therapeutic vaccines for the treatment of chronic hepatitis B
Role of IFN-I in the antitumor efficacy of virotherapy and adoptive cell therapy
Characterization of the antitumor immune response and mechanisms of tumor escape from immune surveillance
Monitoring immune response and searching for predictive biomarkers of responses in clinical trials
Co-inventor of two patents
She has participated in more than 20 research projects, serving as principal investigator in 11 of them. Notable are the competitive projects funded by: Instituto de Salud Carlos III, Government of Navarra, Ministry of Science and Innovation, Ministry of Economy and Competitiveness, European Union, Spanish Association Against Cancer, and private organizations.
She has established 2 agreements and collaborations with R&D&I centers.

Development of personalized TCR cellular therapies
Enhancement of CAR-T therapy through combination with immunomodulators, vaccines, and radiotherapy
Identification of tumor neoantigens and analysis of their value as response biomarkers in clinical trials
T-cell immune monitoring in clinical trials by evaluating changes in the TCR repertoire

She has supervised 3 doctoral theses, 2 of which were awarded the Extraordinary Doctorate Prize from the University of Navarra.
She has contributed to the writing of 2 books.
Associate Professor for the Expert Degree in Immuno-Oncology at Bristol Myers Squibb and the Faculty of Medicine of the University of Navarra.
Invited speaker at more than 10 courses and symposia over the past 5 years. Of note: Invitation to the 10th International Forum on Translational Immunology and Cancer Immunotherapy, Seville, 2024.

She has contributed to the publication of more than 100 scientific articles in international journals and more than 90 presentations at national/international conferences.
Inventor of a TCR targeting the GPC3 tumor antigen for the treatment of hepatoblastomas and hepatocarcinomas.
Participation in clinical trials monitoring immune response and seeking predictive biomarkers of responses. NASIR and ATHECA.